Global Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.

November 2024 | 168 pages | ID: G4DB1FEB2EC6EN
Fatpos Global

Abstracts

Global Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.

Contents

1. EXECUTIVE SUMMARY

2. NON-SMALL CELL LUNG CANCER (NSCLC)

2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. RESEARCH METHODOLOGY

3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. AVERAGE PRICING ANALYSIS

5. MARKET DYNAMICS

5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends

6. CORRELATION & REGRESSION ANALYSIS

6.1. Correlation Matrix
6.2. Regression Matrix

7. RECENT DEVELOPMENT, POLICIES®ULATORY LANDSCAPE

8. RISK ANALYSIS

8.1. Demand Risk Analysis
8.2. Supply Risk Analysis

9. NON-SMALL CELL LUNG CANCER (NSCLC) INDUSTRY ANALYSIS

9.1. Porters Five Forces
  9.1.1. Threat of New Entrants
  9.1.2. Bargaining Power of Suppliers
  9.1.3. Threat of Substitutes
  9.1.4. Rivalry
9.2. PEST Analysis
  9.2.1. Political
  9.2.2. Economic
  9.2.3. Social
  9.2.4. Technological

10. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET

10.1. Market Size & forecast, 2019A-2030F
  10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: MARKET SEGMENTATION

11.1. By Regions
  11.1.1. North America:(U.S. and Canada)
    11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
    11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
    11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
    11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.5. The Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
    11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2. By Histology Market Share (2020-2030F)
  11.2.1. Large cells carcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.2.2. Adenocarcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.2.3. SCC or Squamous cell, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3. By Treatment: Market Share (2020-2030F)
  11.3.1. Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.3.2. Radiation, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.3.3. Surgery, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. COMPANY PROFILE

12.1. Rozlytrek (Entrectinib): Hofmann –La Roche
  12.1.1. Company Overview
  12.1.2. Company Total Revenue (Financials)
  12.1.3. Market Potential
  12.1.4. Global Presence
  12.1.5. Key Performance Indicators
  12.1.6. SWOT Analysis
  12.1.7. Product Launch
12.2. Opdivo (Nivolumab): Bristol-Myers Squibb
12.3. Tagrisso (Osimertinib): AstraZeneca
12.4. Vizimpro (Dacomitinib): Pfizer
12.5. Portrazza (Nacitumumab): Eli Lilly and Company
12.6. Imfinzi (Durvalumab): AstraZeneca.
12.7. Vitrakvi (Larotrectinib): Bayer Healthcare
12.8. Other Prominent Players
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.